<DOC>
	<DOCNO>NCT00392691</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy drug , melphalan , autologous stem cell transplant help stop growth cancer cell , either kill cell stop dividing . Also , monoclonal antibody , yttrium Y 90 ibritumomab tiuxetan rituximab , find cancer cell carry cancer-killing substance without harm normal cell . Chemotherapy monoclonal antibody therapy also prepare patient 's bone marrow stem cell transplant . Giving colony-stimulating factor , G-CSF , vinorelbine help stem cell move bone marrow blood collect store . The stem cell return patient replace blood-forming cell destroy chemotherapy monoclonal antibody therapy . PURPOSE : This phase I trial study side effect best dose melphalan give together yttrium Y 90 ibritumomab tiuxetan rituximab follow autologous stem cell transplant treat old patient non-Hodgkin 's lymphoma relapse respond previous treatment .</brief_summary>
	<brief_title>Melphalan , Yttrium Y 90 Ibritumomab Tiuxetan , Rituximab Followed Autologous Stem Cell Transplant Treating Older Patients With Non-Hodgkin 's Lymphoma That Has Relapsed Not Responded Previous Treatment</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose high-dose melphalan give together yttrium Y 90 ibritumomab tiuxetan rituximab condition regimen follow vinorelbine ditartrate- filgrastim ( G-CSF ) -mobilized autologous stem cell transplantation elderly patient relapse refractory CD20-positive non-Hodgkin 's lymphoma . - Evaluate feasibility safety regimen patient . - Determine feasibility stem cell mobilization vinorelbine ditartrate patient treat regimen . OUTLINE : This multicenter , dose-escalation study high-dose melphalan . - Stem cell harvest mobilization : Patients receive vinorelbine ditartrate IV day -36 filgrastim ( G-CSF ) subcutaneously ( SC ) twice daily day -33 -29 . Patients undergo peripheral blood stem cell harvest day -29 -26 . - Radioimmunotherapy : Patients receive rituximab IV . Within 4 hour completion rituximab , patient receive indium In 111 ibritumomab tiuxetan ( image dose ) IV 10 minute day -25 . Patients undergo assessment biodistribution , imaging , dosimetry day -25 , -22 , optionally day -20 . Patients acceptable biodistribution indium In 111 ibritumomab tiuxetan receive rituximab IV follow yttrium Y 90 ibritumomab tiuxetan ( therapeutic dose ) IV 10 minute day -18 . - High-dose chemotherapy : Patients receive high-dose melphalan IV day -1 . Cohorts 3-6 patient receive escalate dos high-dose melphalan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . - Autologous stem cell transplantation ( ASCT ) : Patients undergo ASCT day 0 . Patients receive G-CSF SC begin day 5 continue blood count recover . After completion study treatment , patient follow 100 day . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma type CD20positive disease Achieved partial complete response salvage treatment relapse refractory disease within past 10 week Must indication autologous stem cell transplantation Bone marrow infiltration &lt; 25 % No evidence CNS involvement PATIENT CHARACTERISTICS : WHO performance status 01 Bilirubin ≤ 2 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN AST ≤ 2 time ULN Creatinine clearance &gt; 50 mL/min No clinically significant cardiac disease , include follow : Unstable angina pectoris Significant arrhythmia Myocardial infarction within past 3 month LVEF &gt; 50 % No clinically significant urinary tract obstruction No clinically significant pulmonary disease No serious underlie medical condition would preclude study participation No malignancy within past 5 year except nonmelanoma skin cancer adequately treat situ cervical cancer PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 30 day since prior participation another clinical trial No prior stem cell transplantation No prior radiolabeled antibody , include induction disease remission No prior radiotherapy ≥ 25 % bone marrow No concurrent radiotherapy No concurrent anticancer drug No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
</DOC>